Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27795085 | 0.90 | GABRA1 (0.64) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL1558405 | 0.87 | NR4A2 (0.61) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL22122306 | 0.86 | CYP2A6 (0.51) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL5434549 | 0.86 | NR4A2 (0.69) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL2085712 | 0.86 | NR4A2 (0.69) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL1612772 | 0.83 | LMNA (0.68) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL4685934 | 0.83 | NR4A2 (0.65) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL1612926 | 0.83 | NR4A2 (0.69) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL16920166 | 0.82 | NR4A2 (0.60) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL26204080 | 0.82 | NR4A2 (0.64) | NR4A2GABRA1GABRB1GABRA3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | NR4A2 1597/4885GABRA1 3625/4885GABRB1 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.